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Infections and bleeding are the most frequent causes of death in patients with bone marrow failure secondary to chemotherapy/radiotherapy for malignant disease. Treatment of anemia and severe thrombocytopenia has been dependent solely on red blood cell (RBC) and platelet transfusion. With the recent availability of recombinant hematopoietic CSFs, stimulation of hematopoiesis in vivo has evolved as a new, potentially efficacious treatment modality. The feasibility of this approach is supported by several clinical studies showing that two distinct CSFs, granulocytemacrophage CSF (GM-CSF) and granulocyte CSF (G-CSF), can indeed elevate total leukocyte counts in patients with bone marrow f a i l~r e . '~.~~ However, improvements in erythropoiesis and thrombopoiesis were observed only sp~radically.'~,'~.'~ Preclinical studies have demonstrated that IL-3 effectively stimulates myelopoiesis, erythropoiesis, and thrombopoiesis in several murine and nonhuman primate model^.^^.^' On the basis of these data and the availability of sufficient quantities of human IL-3 (rhIL-3) produced by recombinant DNA technique^,^^.^' we have treated 19 patients with advanced malignancy but with preserved bone-marrow function and 9 patients with secondary bone-marrow failure in a phase 1/11 study to evaluate the safety and hematologic effects of subcutaneous injections of rhIL-3. Our data demonstrate the capacity of rhIL-3 to stimulate myelopoiesis, thrombopoiesis, and, to a lesser degree, erythropoiesis at dose levels well tolerated by these patients.
METHODS
In a phase 1/11 study, 19 consecutive patients with advanced malignancies and preserved hematopoietic function and 9 patients with secondary bone-marrow failure and severe cytopenia were treated with rhIL-3: 22 men and 6 women ranging in age from 18 to 77 years (median, 54 years). The underlying diseases and previous therapies are listed in Tables 1 and 2 . Bone marrow hypoplasia due to prolonged chemotherapy for cancer and additional tumor infiltration of the bone marrow (n = 3) but no evidence of secondary myelodysplasia was apparent in 9 patients and confirmed by bone marrow cytology and histology. These patients had received the last previous dose of chemotherapy 3 weeks to 14 months (median: 2.5 months) prior to initiation of rhIL-3 treatment. Three of these patients had received additional radiotherapy. Three patients had been treated with recombinant GM-CSF at 6 weeks, 4 months, and 8 months before entering the present trial, without persisting improvements of peripheral blood counts. In no patient was there any evidence of spontaneous hematopoietic recovery. None of the patients had clinical evidence of bacterial, fungal, or viral infections when entering this study. Seventeen of 19 patients with preserved hematopoietic function had received cytotoxic therapy prior to the administration of IL-3. However, apart from a slightly reduced mean hemoglobin concentration, there were no further signs of hematopoietic dysfunction nor any evidence that rhIL-3 was administered during the recovery phase from previous chemotherapy. One patient with preserved hematopoietic function treated at a Patient selection. dose level of 500 pg/m2 and 1 patient with secondary hematopoietic failure also treated at 500 pg/m2 were only evaluable for toxicity but not for hematologic response because rhIL-3 had to be discontinued after 2 and 5 days of treatment, respectively.
Eligibility criteria included a performance status of more than 50% (Karnofsky scale); life expectancy of more than 3 months; preserved hepatic, renal, cardiac, and hemostaseologic function; and absence of clinically apparent allergies or bronchoalveolar disorders.
The study was approved by the Ethics Committee of the University of Frankfurt. Informed written consent was obtained from the patients prior to rhIL-3 therapy.
Recombinant human IL-3. The cDNA of rhIL-3 was isolated from human peripheral blood lymphocytes and the gene product expressed in yea~t.'~ The molecular weight was in a range of 14 to 16 Kd. The rhIL-3 used in this study was provided by Behringwerke AG (Marburg, FRG). Specific activity of this material was >1 x lo7 U/mg protein in a bone marrow proliferation assay. Sterility, pyrogenicity, general safety, and purity studies met O f f i c e of Biologics standard. No endotoxin was measurable with the limulus amebocyte lysate assay (less than 10 pg/mg protein).
Recombinant human IL-3 was given by subcutaneous bolus injection daily for 15 days. The treatment schedule consisted of increasing dose levels of rhIL-3 (ie, 30 pg/m2, 60 pg/m2, 125 pg/m2, 250 pg/m2, and 500 pg/m2). However, the individual patients were treated only at one dose level. The first dose on day 1 was administered over 5 minutes as an intravenous (IV) bolus injection to determine the pharmacokinetics of rhIL-3. Because transient acrocyanosis and chills occurred in the first three patients receiving 125 pg/m2, the mode of administration was changed and bolus injection on day 1 was omitted in all subsequent patients.
Patients were monitored daily, and all constitutional symptoms were recorded. Before and during the study, patients were regularly monitored by means of complete history and physical examination and laboratory tests, including a complete blood count (CBC), differential and reticulocyte counts, a chemistry profile, coagulation profile, and urinalysis. An electrocardiogram (ECG) and chest radiograph were performed before the study and after the final dose. Bone marrow aspirates and biopsy specimens were processed according to conventional methods and evaluated before and after the treatment cycle. For
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The student's t test was used for calculating the mean f SEM. The Wilcoxon signed-rank test for paired data was used to test for significant differences between data before and after administration of rhIL-3.
Toxicity was graded according to the World Health Organization (WHO) criteria.36 Dose-limiting toxicity was generally defined as toxicity of grade 3 or higher by WHO criteria. Red blood cell concentrates were given if the hemoglobin level dropped below 8 g/dL or if there were symptoms related to anemia. Platelet transfusions were only given in cases of bleeding. Antipyretics were not given unless the body temperature rose to greater than 39°C.
RESULTS

Patients with preserved hematopoietic function.
The patients' clinical responses to therapy are shown in Table 3 and Figs 1 and 2. In response to subcutaneous daily administration of rhIL-3, the leukocyte counts rose in a dosedependent manner (Fig 1A) . After the second week of treatment, mean peak-leukocyte counts rose 1.1-fold (at a daily dose of 60 Mg/m2) to 2.8-fold (at a dose of 500 rg/m'). The increase in leukocytes was primarily due to a dosedependent increase in segmented neutrophils, eosinophils, and lymphocytes. Circulating neutrophil levels increased dose dependently up to 2.7-fold at 500 pg/m2. The kinetics of the elevation in neutrophil counts is shown in Figs 1 B and 2 . Despite a gradual increase after 3 to 4 days of treatment, more than a week elapsed before the neutrophil counts rose conspicuously. There were no changes in leukocyte counts within the first 12 hours after the rhIL-3 administration. After discontinuation of treatment, neutrophil numbers returned to baseline levels within 1 to 2 weeks. However, in individual patients they could remain elevated for longer periods (Fig 2) . Although band neutrophils increased, more immature myeloid cells (ie, myelocytes and metamyelocytes) were only rarely detectable in the blood smears. Reversible Table 3 for absolute counts. (asterisk. 60 pg/m2; circle, 125 pglm2: square, 250 pg/m2: triangle. 500 pg/ m2). 
Days
eosinophilia occurred at all dose levels ranging between 1074/pL and 3788/pL. Basophil counts also increased up to 12-fold at 250 pg/m2 but did not reach pathologic levels. Both T-helper and T-suppressor lymphocytes were increased between 1.9-and 2.4-fold after treatment.
A dose-dependent increase in platelet counts was observed in 15 of 18 evaluable patients with preserved bone marrow function ranging from 1.3-fold at 60 pg/m2 to 1 .!&fold at 250 pg/m*. As shown in Fig 3, the time until the platelets actually rose was equally dose dependent, with earlier mf 'O01 , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , increases at the higher dosages. The platelet counts continued to rise for an additional week after discontinuation of rhIL-3 treatment before returning to baseline levels over a period of 2 to 3 weeks. Patients with elevated initial platelet counts did not exhibit the same degree of response to rhIL-3 as did patients with normal counts (Fig 3) . A decrease in the mean platelet volume from 7.7 * 0.3 fL to 7.2 * 0.3 fL (P < .05) in 11 patients tested accompanied the rise in platelet counts.
A delayed increase in reticulocyte counts occurring after day 10 of treatment was observed in 14 patients (Table 3) ; maximum values were reached between days 15 and 20. However, no dose-response relationship was present. In two patients the increase in reticulocytes was followed by a rise of the hemoglobin level by more than 1 g/dL. Serum IgM levels were measured in 15 patients prior to and after treatment with rhIL-3. They increased from 1.27 f 0.26 g/L to 2.10 * 0.55 g/L (P < .01). A correlation to the dosage of rhIL-3 was not observed. Serum IgG, IgA, and IgE did not change significantly.
The total leukocyte counts as well as the circulating neutrophil counts rose in all evaluable eight patients in response to rhIL-3 ( Table 4) . As compared to patients with preserved hematopoietic function, the rise in circulating leukocytes was more delayed, but eventually seven of eight patients achieved neutrophil counts above 2,OOO/pL, and no patient had a count below SOO/pL after treatment. The median time to Patients with secondary hematopoietic failure.
peak neutrophil counts was 19 days (range, 6 to 50). Eosinophils, basophils and monocytes all peaked at a median time of 13 to 16 days (range, 14 to 46 days for eosinophils, 8 to 50 days for basophils, and 11 to 46 days for monocytes).
A stimulation of thrombopoiesis with a subsequent 1.3-to 14.3-fold (mean, sixfold) increase in circulating platelet numbers occurred in five of eight evaluable patients (Fig 4) . This increase resulted in discontinuation of platelet transfusions in two out of three evaluable patients who had been dependent on repeated substitution. Reticulocyte counts responded to administration of rhIL-3 in six of eight patients. The reticulocyte counts reached the maximum a t a median of 8 days (range, 2 to 65) and rose 1.2-to 16.6-fold (mean, 4.4-fold). The necessity of RBC transfusions was, however, not reduced during the observation period. Serum IgM levels increased dose independently in all eight evaluable patients from 0.73 0.12 g/L to 2.50 + 0.99 g/L ( P < .01). Mean serum IgG and IgA levels did not change.
The histologic analysis of bone marrow biopsies obtained before and after the treatment cycles demonstrated an increase in cellularity from 39.5% to 63.2% (n = 6; P < .05) in patients with normal hematopoietic function (Fig 5) , along with increases in megakaryocytes and eosinophils but not in basophils (Table 5 ) . Bone marrow cellularity also increased in six of eight patients with bone marrow failure. Granulopoiesis was shifted to the left with increased percentages of promyelocytes and myelocytes, while the percentage of lymphocytic elements decreased Cellularity. from 11.6% 2.5% to 6.7% 1.4% ( P < .05). The increase in the percentage of immature myeloid cells was also apparent in four of eight patients with bone marrow failure. In one patient (patient 7), this profound shift to the left with 9% blast cells was accompanied by morphological abnormalities resembling a myelodysplastic syndrome with excess of blasts (Fig 6) . There were no increases in bone marrow infiltrating tumor or lymphoma cells.
Megaksnlocytert
Toxicity of the treatment schedule was mild. Fever, not exceeding 4OoC, was seen in the majority of patients and was usually more pronounced during the first few days of therapy (Table 6) . Headache accompanied by stiffness of the neck was a common finding, leading to a dose reduction in one patient initially treated with 250 pg/m2. In one patient a t 500 pg/m2, rhIL-3 had to be discontinued after 2 days because of development of pneumonia. In a further patient a t 500 pg/m*, rapid increase in the size of an already progressing osteosarcoma led to discontinuation of rhIL-3 treatment after 5 days and the immediate start of chemotherapy. Mild local erythema at the site of subcutaneous injection of rhIL-3 was observed in several patients. Apart from facial flushing during the whole 2 weeks of treatment in two patients receiving 250 pg/m2 and 500 pg/m2, respectively, there were no side effects attributable to histamine release.
Possible effects of rhIL-3 on neoplastic cells included a transient rise in circulating atypical B lymphocytes in one patient with follicular, mixed, small-cleaved and large-cell lymphoma receiving 60 pg rhIL-3/m2 and in one patient with diffuse large-cell lymphoma treated with 250 pg/m2. The latter patient also developed palpable lymph nodes and an increase in spleen size that were reversible within 2 weeks Adverse effects of recombinant ZL-3.
after discontinuation of rhIL-3. No increase in paraprotein levels was observed in the two patients with multiple myeloma.
DISCUSSION
Treatment with rhIL-3 clearly induced a multilineage response with an increase in leukocytes, platelets, and reticulocytes both in patients with preserved hematopoietic function and in patients with bone marrow failure and longlasting cytopenias. In contrast to the rapid rise in leukocyte counts after treatment with GM-CSF'3-'8J7 or G-CSF,38-40 the clear but lower magnitude of the leukocytosis induced by rhIL-3 and the somewhat delayed response are consistent with the concept that rhIL-3 exerts its principal action at the level of multipotent and committed hematopoietic progenitor cell^^-^ and not at the level of morphologically recognizable myeloid precursor cells in the bone marrow.6 Mobilization of cells from the bone marrow or marginal pool within hours after administration of rhIL-3, as suggested for GM-CSF'3.'8 or G-CSF,38,39 did not occur. The increase in leukocyte counts was sustained even after the end of treatment with marked increases in cellularity and shift to the left of myelopoiesis in the bone marrow, further indicating an effect at an early stem progenitor-cell level.
The most important and clinically promising response to rhIL-3 was the increase in platelet and reticulocyte counts that could be of value after chemotherapy or bone marrow transplantation. The basis of this response again seems to be the stimulation at the level of the multipotent and lineagecommitted progenitor cells, resulting in the delayed response time of platelets and reticulocyte^.^-^^^'^^^ IL-3 is a potent, 
